SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs has drawn attention, with traders citing BRIUMVIs sales growth and the Q3 results and subcutaneous Phase 3 data as key business catalysts. Buyout speculationparticularly involving Sanofiand hopes for short covering are widespread, but no deal is confirmed; some investors argue that execution matters more than takeover chatter.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is discussing access to a large number of U.S. cell sites have focused attention on Crown Castle as traders weigh potential new tower-leasing demand for Starlink Mobile. Bulls see a hybrid satellite-and-terrestrial network as a boost for tower owners, while skeptics note that no agreement is signed and question execution, regulatory approval, and whether speculation has already driven the move.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,967,326.643147 in circulation. The last known price of Algorand is 0.09515711 USD and is down -0.23 over the last 24 hours. It is currently trading on 586 active market(s) with $49,581,617.87 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention around a contested recovery thesis: bullish traders cite technical support, rebounds and a possible altcoin rotation, while bears point to persistent underperformance and the risk of further declines. Some bulls also highlight Algorands quantum-resistant technology and tokenization or payment use cases, though these are longer-term narratives rather than a confirmed near-term catalyst.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

A volatile LINK rebound and repeated resistance tests are driving discussion, with bulls pointing to Chainlinks institutional and tokenization integrations, including its role in Coinbases Base tokenized-stock offering and CCIP 2.0. Skeptics warn that rallies have faded before and question whether network adoption will translate into value for the LINK token.

Bitdeer Technologies Group engages in the cryptocurrency mining industry. It generates income through its proprietary mining datacenters. The firm handles complex processes involved in computing such as equipment procurement, transport logistics, datacenter design and construction, equipment management, and daily operations. The company was founded by Wu Jihan in December 2021 and is headquartered in Singapore.

Bitdeer Technologies Group. - Ordinary Shares - Class A

Bitdeer Technologies Holding Co

BTDR is under pressure alongside Bitcoin miners and AI infrastructure stocks as traders cite Bitcoin weakness and a recent downgrade; some also blame short-selling, though that remains speculation. The community is split between calling the selloff an opportunity ahead of earnings and worrying the decline could continue, with many frustrated by BTDRs lagging performance versus peers.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas upcoming addition to the S&P 500 is a major topic, with traders weighing expected index-fund buying against a possible sell-the-news move as the shares weaken. Some posts also cite an alleged DHS-related breach, but those claims are unverified in the discussion.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans strong third-quarter results, higher full-year outlook and record backlog are driving discussion, with traders pointing to sustained defense demand. The reaction is mixed: some see the fundamentals as support for the shares, while others question the rally and expect a pullback.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is drawing attention after dazodalibep met its Phase 3 endpoint in Sjgrens disease, with traders viewing the result as a pipeline catalyst. The discussion also cites strong IMDELLTRA/Imfinzi small-cell lung cancer data, alongside questions about whether recent momentum is already priced in.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

A newly disclosed performance-based option award for CEO Gregory Demopulos is drawing attention, with traders debating whether its stock-price and service conditions align his incentives with shareholders. The broader discussion remains focused on YARTEMLEAs U.S. sales growth and the next quarterly results, with bullish expectations balanced by caution after the European regulatory rejection.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Q4 topline results from its Phase 3 HLP003 trial for major depressive disorder, a pivotal catalyst for the clinical-stage biotech. Traders are optimistic about the treatments potential as an add-on to existing antidepressants, but debate the binary trial risk, possible dilution and how results could compare with peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) delivered earnings and revenue surprises of +7.69% and +1.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr...

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STAAR Surgical to Participate in Upcoming Investor Conferences

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA) SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday...

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

STAAR Surgical Company (STAAR or the Company) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report...

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA). SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation...

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent...

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Staar Surgical Co.

STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Wedbush said the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.</li><li>Canaccord stated that even though it updated its model for Staar Surgical, the company provided very little information compared to its April preannouncement.</li><li>The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million</li></ul>&nbsp;Shares of Staar Surgical (STAA) shot up more than 10% on Thursday after multiple analysts turned bullish on the stock following strong quarterly results.Wedbush updated Staar Surgical to ‘Outperform’ from a ‘Neutral’ rating and hiked its price target to $40 from $26,&nbsp;representing a 53% hike from the firm's previous estimate.<h2 class="st-heading-2">Wedbush Says STAA Has Potential To Exceed Its Bull Case Scenario</h2>Wedbush stated that Staar Surgical’s first-quarter earnings report indicates the company is either at or nearing the inflection point for a full recovery in China, according to TheFly.The firm also stated that it has taken a long-term bet on the company, as Staar Surgical has the potential to exceed its bull-case scenario in the upcoming quarters, and it would prefer to be early rather than late on Staar Surgical’s growth story.&nbsp;&nbsp;It added that the recovery in China may prompt a valuation re-rating of the stock and multiple expansion to historical levels.Meanwhile, Canaccord increased Staar Surgical’s price target to $32 from $27 and kept a ‘Buy’ rating. The firm noted that the quarterly report provides a strong foundation for the remainder of 2026. However, Canaccord stated that even though it updated its model for the stock, the company provided very little information compared to its April preannouncement.&nbsp;Adam Maeder, analyst at Pipe Sandler, raised the company stock price target to $33 from $16. Maeder noted that Staar Surgical’s Chinese business was impressive. He added that the company’s first-quarter results were in line with its preannouncement in April; however, despite a good start to the year, the company did not provide full-year guidance or add more information on the second-quarter outlook.<h2 class="st-heading-2">Staar Surgical’s Q1 Earnings Report</h2>The company reported first-quarter net sales of $93.5 million, beating Wall Street expectations of $78.72 million, while earnings stood at $0.10 per share compared to a loss of $1.10 per share in the year-ago quarter.Regarding its China business, the company stated that net sales in China were mainly driven by a recovery in in-market demand, positioning it better for the second quarter and the rest of the year.<h2 class="st-heading-2">What Retail Thinks About STAA Stock</h2>On Stocktwits, retail sentiment surrounding the stock has improved to ‘extremely bullish’ from ‘bullish’, while message volume improved to ‘extremely high’ from ‘normal’ in the past 24 hours.Shares of Staar Surgical have gained more than 38% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/amd-lisa-su-ai-agents-driving-tremendous-demand-amd-stock-q1-earnings/cZQzIIAReO5">AMD's Lisa Su Says AI Agents Are Driving ‘Tremendous Demand’, Touts Chipmaker's Portfolio Amid Blowout Q1</a>

In this photo illustration, the Staar Surgical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wedbush stated that Staar Surgical could be at or near an inflection point for a full China rebound, according to TheFly. 

STAA Stock On Track For Its Fourth Straight Session Of Gains –  This Analyst Would Rather Be Early Than Late On Staar’s Growth Story

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$STAA Sentiment starting to turn around... The future of refractive surgery- it's a rEVOlution!

Cheese

$STAA Neal continues to communicate to us in code. Today's BD appointment from JNJ was to foreshadow the acquieree. The $50M repurchase authorization foreshadows the buyout price of $50, and David Bailey rejoining implies it will be sooner than later

Feed

News

Sentiment

Earnings

Fundamentals

Info

STAA Staar Surgical Co.

Fundamentals

Latest STAA News